Identification
- Summary
Sodium phosphate, monobasic, unspecified form is an osmotic laxative used to cleanse the colon before a colonoscopy.
- Brand Names
- Fleet Mineral Oil, Pedia-lax Liquid, Urogesic Blue Reformulated Apr 2012, Utira
- Generic Name
- Sodium phosphate, monobasic, unspecified form
- DrugBank Accession Number
- DB14503
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved
- Synonyms
- Not Available
Pharmacology
- Indication
Used to treat constipation or to clean the bowel before a colonoscopy Label.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Sodium phosphate inceases fecal water content to increase mobility through the large intestine 1.
- Mechanism of action
Sodium phosphate is thought to work by increasing the amount of solute present in the intestinal lumen thereby creating an osmotic gradient which draws water into the lumen 1.
- Absorption
Tmax for phosphate absorption with orally administered liquid sodium phosphate is 1-3h 3.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Intamuscular LD50 of 250mg/kg and oral LD50 of 8290 mg/kg reported in rats 7. Phosphate toxicity is likely due to the disturbance of other electrolytes when phosphate levels are high, producing symptoms including tetany, dehydration, hypotension, tachycardia, hyperpyrexia, cardiac arrest and coma 4. Risk of raising phosphate levels through use of sodium phosphate appears to be higher in smaller patients 3.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetazolamide The risk or severity of dehydration can be increased when Acetazolamide is combined with Sodium phosphate, monobasic, unspecified form. Aclidinium The therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Aclidinium. Alfentanil The therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Alfentanil. Alloin The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic, unspecified form is combined with Alloin. Almasilate The therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Almasilate. Aluminium phosphate The therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Aluminium phosphate. Aluminum hydroxide The therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Aluminum hydroxide. Amantadine The therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Amantadine. Amiloride The risk or severity of dehydration can be increased when Amiloride is combined with Sodium phosphate, monobasic, unspecified form. Amiodarone The therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Amiodarone. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Take with a full glass of water.
- Take with food.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Phosphoric acid unknown E4GA8884NN 7664-38-2 NBIIXXVUZAFLBC-UHFFFAOYSA-N Sodium cation ionic LYR4M0NH37 17341-25-2 FKNQFGJONOIPTF-UHFFFAOYSA-N Phosphate ion ionic NK08V8K8HR 14265-44-2 NBIIXXVUZAFLBC-UHFFFAOYSA-K - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Care One Enema Sodium phosphate, monobasic, unspecified form (19 g/118mL) + Sodium phosphate, dibasic, unspecified form (7 g/118mL) Enema Rectal American Sales Company 2010-01-18 2014-06-07 US 
Curad Oral Saline Laxative Sodium phosphate, monobasic, unspecified form (7.2 g/15mL) + Sodium phosphate, dibasic, unspecified form (2.9 g/15mL) Liquid Oral Medline Industries 2012-07-16 2016-12-31 US Curad Oral Saline Laxative Sodium phosphate, monobasic, unspecified form (7.2 g/15mL) + Sodium phosphate, dibasic, unspecified form (2.9 g/15mL) Liquid Oral Medline Industries 2012-07-16 2016-12-31 US Curad Saline Laxative Sodium phosphate, monobasic, unspecified form (19 g/118mL) + Sodium phosphate, dibasic, unspecified form (7 g/118mL) Enema Rectal Medline Industries, Inc. 2012-07-16 2017-01-01 US CVS Pharmacy Sodium phosphate, monobasic, unspecified form (9.5 g/59mL) + Sodium phosphate, dibasic, unspecified form (3.5 g/59mL) Enema Rectal CVS Health 2014-05-20 Not applicable US CVS Pharmacy Sodium phosphate, monobasic, unspecified form (19 g/118mL) + Sodium phosphate, dibasic, unspecified form (7 g/118mL) Enema Rectal CVS PHARMACY 2013-03-08 Not applicable US Discount Drug Mart Enema Sodium phosphate, monobasic, unspecified form (19 g/118mL) + Sodium phosphate, dibasic, unspecified form (7 g/118mL) Enema Rectal Discount Drug Mart 2013-12-27 Not applicable US Enema Sodium phosphate, monobasic, unspecified form (19 g/118mL) + Sodium phosphate, dibasic, unspecified form (7 g/118mL) Enema Rectal Medicine Shoppe International 2009-11-20 2015-04-22 US Enema Sodium phosphate, monobasic, unspecified form (19 g/118mL) + Sodium phosphate, dibasic, unspecified form (7 g/118mL) Enema Rectal Western Family Foods 2009-12-31 2015-04-22 US Enema Sodium phosphate, monobasic, unspecified form (19 g/118mL) + Sodium phosphate, dibasic, unspecified form (7 g/118mL) Enema Rectal Rite Aid 2009-11-18 2015-04-22 US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Darcalma Sodium phosphate, monobasic, unspecified form (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (81.6 mg/1) + Methylene blue trihydrate (10.8 mg/1) + Phenyl salicylate (36.2 mg/1) Tablet Oral River's Edge Pharmaceuticals, LLC 2008-12-22 2011-07-31 US Darcalma Sodium phosphate, monobasic, unspecified form (40.8 mg/1) + Hyoscyamine sulfate dihydrate (.12 mg/1) + Methenamine (81.6 mg/1) + Methylene blue trihydrate (10.8 mg/1) + Phenyl salicylate (36.2 mg/1) Tablet Oral Kylemore Pharmaceuticals, LLC 2009-12-01 2009-12-02 US OroMin Sodium phosphate, monobasic, unspecified form (0.056 g/100g) + Calcium chloride dihydrate (0.054 g/100g) + Sodium fluoride (0.01 g/100g) Rinse Dental Germiphene Corporation 2017-06-16 Not applicable US Uro-BLUE Sodium phosphate, monobasic, unspecified form (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (81.6 mg/1) + Methylene blue trihydrate (10.8 mg/1) Tablet Oral Method Pharmaceuticals 2014-12-01 2015-07-06 US Urogesic Blue Sodium phosphate, monobasic, unspecified form (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (81.6 mg/1) + Methylene blue trihydrate (10.8 mg/1) Tablet Oral Edwards Pharmaceuticals, Inc 2010-04-30 2017-12-30 US Urogesic Blue Sodium phosphate, monobasic, unspecified form (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (81.6 mg/1) + Methylene blue trihydrate (10.8 mg/1) Tablet, coated Oral EDWARDS PHARMACEUTICALS, INC. 2010-11-19 Not applicable US Urolet Mb Sodium phosphate, monobasic, unspecified form (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (81.6 mg/1) + Methylene blue trihydrate (10.8 mg/1) Tablet Oral Burel Pharmaceuticals, Llc 2015-06-26 2016-10-23 US Uta Sodium phosphate, monobasic, unspecified form (40.8 mg/206.92mg) + Hyoscyamine sulfate dihydrate (.12 mg/206.92mg) + Methenamine (120 mg/206.92mg) + Methylene blue trihydrate (10 mg/206.92mg) + Phenyl salicylate (36 mg/206.92mg) Capsule Oral STEWART-JACKSON PHARMACAL, INC 2002-08-01 2016-03-08 US Uta Sodium phosphate, monobasic, unspecified form (40.8 mg/170.92mg) + Hyoscyamine sulfate dihydrate (0.12 mg/170.92mg) + Methenamine (120 mg/170.92mg) + Methylene blue trihydrate (10 mg/170.92mg) Capsule Oral Sj Pharmaceuticals, Llc 2014-09-26 2019-01-24 US Utira-C Sodium phosphate, monobasic, unspecified form (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (81.6 mg/1) + Methylene blue trihydrate (10.8 mg/1) + Phenyl salicylate (36.2 mg/1) Tablet Oral Mission Pharmacal Company 2011-09-11 Not applicable US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 3980JIH2SW
- CAS number
- Not Available
References
- General References
- Rex DK: Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy. Ann Pharmacother. 2007 Sep;41(9):1466-75. Epub 2007 Jul 24. [Article]
- Schanz S, Kruis W, Mickisch O, Kuppers B, Berg P, Frick B, Heiland G, Huppe D, Schenck B, Horstkotte H, Winkler A: Bowel Preparation for Colonoscopy with Sodium Phosphate Solution versus Polyethylene Glycol-Based Lavage: A Multicenter Trial. Diagn Ther Endosc. 2008;2008:713521. doi: 10.1155/2008/713521. [Article]
- Ehrenpreis ED: Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis. Aliment Pharmacol Ther. 2009 Jun 1;29(11):1202-11. doi: 10.1111/j.1365-2036.2009.03987.x. Epub 2009 Feb 27. [Article]
- Razzaque MS: Phosphate toxicity: new insights into an old problem. Clin Sci (Lond). 2011 Feb;120(3):91-7. doi: 10.1042/CS20100377. [Article]
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- FDA Guide: Sodium Phosphate Tablet [Link]
- ChemIDPlus: Sodium Phosphate [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Unknown Status Treatment Malnutrition 1 2 Active Not Recruiting Treatment Acute Malnutrition, Severe Acute Malnutrition / Sickle Cell Anemia 1 1 Completed Not Available Healthy Subjects (HS) 1 1 Completed Treatment Type 1 Diabetes Mellitus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral Liquid Rectal Solution Intravenous Kit Intravenous Liquid Oral Rinse Dental Enema Rectal Tablet, coated Oral Capsule Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Not Available
- Specific Function
- Not Available
- Gene Name
- SLC20A1
- Uniprot ID
- Q8WUM9
- Uniprot Name
- Sodium-dependent phosphate transporter 1
- Molecular Weight
- 73699.01 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Virus receptor activity
- Specific Function
- Sodium-phosphate symporter which seems to play a fundamental housekeeping role in phosphate transport by absorbing phosphate from interstitial fluid for normal cellular functions such as cellular m...
- Gene Name
- SLC20A2
- Uniprot ID
- Q08357
- Uniprot Name
- Sodium-dependent phosphate transporter 2
- Molecular Weight
- 70391.755 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Sodium:phosphate symporter activity
- Specific Function
- Involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 70-80% of the apical influx.
- Gene Name
- SLC34A1
- Uniprot ID
- Q06495
- Uniprot Name
- Sodium-dependent phosphate transport protein 2A
- Molecular Weight
- 68936.53 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Sodium:phosphate symporter activity
- Specific Function
- May be involved in actively transporting phosphate into cells via Na(+) cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the s...
- Gene Name
- SLC34A2
- Uniprot ID
- O95436
- Uniprot Name
- Sodium-dependent phosphate transport protein 2B
- Molecular Weight
- 75758.535 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Sodium:phosphate symporter activity
- Specific Function
- May be involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 20-30% of the apical influx.
- Gene Name
- SLC34A3
- Uniprot ID
- Q8N130
- Uniprot Name
- Sodium-dependent phosphate transport protein 2C
- Molecular Weight
- 63548.94 Da
References
- Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [Article]
Drug created at July 11, 2018 17:37 / Updated at January 08, 2021 01:07